Skip to content
Companies

Autonomy Bio

RNA therapies that activate only in cancer cells

Raised to date

$17M

of $17M offered across 1 Form D filing

Investors
8
Last filed
Mar 27, 2025

About

Autonomy Bio Inc. is an innovative biotechnology firm focused on advancing RNA-based therapeutics specifically designed to address challenging diseases, with a strong emphasis on oncology and infectious diseases. Leveraging proprietary technology, the company is committed to enhancing the precision and effectiveness of treatments to improve patient outcomes for complex conditions.

Autonomy Bio stands out with its proprietary encrypted RNA technology that enables targeted therapeutic effects only in diseased cells, minimizing side effects on healthy cells.

Funding

  • EquityFiled Mar 27, 2025Form D
    $17M/ $17M

Product

Encrypted RNA (encRNA)

RNA therapeutics

EncRNA is a groundbreaking class of RNA therapeutics engineered for precision targeting of malignant cells, ensuring that therapeutic interventions activate specifically within cancer cells. This mechanism aims to enhance treatment efficacy while reducing the risk of toxicity associated with standard therapies.

  • Precision targeting of diseased cells
  • Cancer-activated therapeutic protein translation
  • Minimized side effects on healthy tissue

Built for

Pharmaceutical companies and research institutions

People on file